| Project/Area Number |
17K15786
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Kyoto Tachibana University (2018-2020)
Tenri Health Care University (2017) |
|---|
Principal Investigator |
OKADA KOHKI 京都橘大学, 健康科学部, 助教C (80747569)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | S100タンパク質 / 炎症性腸疾患 / 潰瘍性大腸炎 / マクロファージ / バイオマーカー / 臨床検査 / クローン病 / トランスジェニックラット / transgenic rat / S100 protein / macrophage / ulcerative colitis |
|---|
| Outline of Final Research Achievements |
The initial aim of this study was to establish transgenic rats with high expression of S100A9 on their whole body (Tg-S100A9), and to elucidate the relationship between the immunological function of S100A9 and the development of ulcerative colitis (UC). However, due to the difficulty in establishing Tg-S100A9, we shifted our research focus to the discovery of biomarkers for UC.
We found that serum S100A8/A9, complement C3, and alpha-2-macroglobulin were more sensitive biomarkers for UC than C-reactive protein (CRP), and their serum levels were novel indexs for the severity of UC. In addition, by animal experiment, we confirmed that circulating S100A8/A9, carbonic anhydrase Ⅲ, and transgelin also reflect the severity of UC. These findings would contribute to advance of laboratory medecine and medical examination for UC in the future. Our effort to scrutinize potentiality of serum biomarkers is in progress.
|
| Academic Significance and Societal Importance of the Research Achievements |
日本では平成29年12月より, UC患者の便中S100A8/A9測定が保険適応された。一方で, 重症のUCでは激しい下痢と下血を伴い採便が困難である。大腸内視鏡は医師のみが実施可能な検査であり, 時間とコストを要する。CRP測定などの血液検査も特異性に欠けるため, 既存のUC検査法はいずれも弱点があると言わざるを得ない。本研究の成果は, これら種々の問題を解消する新たなUC検査法の構築に繋がる。具体的には, 患者には大腸内視鏡の回数削減に繋がり, 身体的・精神的負担の軽減に寄与する。また, UCの検査法が確立することは, 医師および臨床検査技師の負担や医療過誤の削減にも貢献する。
|
